TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Show more
Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate patients switching from prior anti-CD20...
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained...
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire NEW YORK, Sept. 6, 2024 NEW YORK...
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I &...
Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 - $300 million Cash flow positive for second quarter...
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.04 | 8.75160875161 | 23.31 | 26.41 | 23.31 | 3930923 | 24.88972992 | CS |
4 | 0.83 | 3.38499184339 | 24.52 | 26.41 | 21.11 | 3179316 | 23.717184 | CS |
12 | 7.34 | 40.7551360355 | 18.01 | 26.41 | 16.8901 | 3182110 | 21.82958596 | CS |
26 | 10.15 | 66.7763157895 | 15.2 | 26.41 | 12.93 | 3077043 | 18.70523407 | CS |
52 | 15.76 | 164.337851929 | 9.59 | 26.41 | 6.46 | 4189171 | 15.37253451 | CS |
156 | -4.73 | -15.7247340426 | 30.08 | 35.94 | 3.48 | 3702555 | 14.21688714 | CS |
260 | 18.95 | 296.09375 | 6.4 | 56.74 | 3.48 | 2920571 | 16.88550491 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.